286 related articles for article (PubMed ID: 15476575)
41. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
42. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Isahaya E; Hara N; Nishiyama T; Hoshii T; Takizawa I; Takahashi K
Prostate; 2010 Feb; 70(2):155-61. PubMed ID: 19760629
[TBL] [Abstract][Full Text] [Related]
43. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
44. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
Wadhwa VK; Parr NJ
Urology; 2009 Jun; 73(6):1347-51. PubMed ID: 19362345
[TBL] [Abstract][Full Text] [Related]
45. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Smith MR
Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
[TBL] [Abstract][Full Text] [Related]
46. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
47. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
48. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
49. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
[TBL] [Abstract][Full Text] [Related]
50. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
51. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
52. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
[TBL] [Abstract][Full Text] [Related]
53. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
54. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
55. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
56. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
Yaturu S; DjeDjos S; Alferos G; Deprisco C
Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
[TBL] [Abstract][Full Text] [Related]
57. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
58. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
[TBL] [Abstract][Full Text] [Related]
59. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
Izumi K; Mizokami A; Namiki M
Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
[TBL] [Abstract][Full Text] [Related]
60. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
Ishizaka K; Machida T; Yoshida K
Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]